The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive ...

Andrew G. Lee, MD, and Drew Carey, MD, return for this episode of 'NeuroOp Guru' to discuss how sixth nerve palsy with ...

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest ...

The May 4 event, themed around Star Wars, will feature the latest innovations, foster open discussions, and provide a ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss.

Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Labtician Ophthalmics has announced the commercial launch of Lab TRIACTIV, an artificial tear designed to redefine dry eye ...